Gordon & Ramirez ,
-
FDA pilots real-time clinical trials to speed safety review
The FDA says it has started two proof-of-concept clinical trials that will send some endpoints and data signals to the agency in real time. The agency is also asking for input on a pilot program that could begin this summer. For readers, the big question is not whether trial oversight is changing today, but whether this early test can improve safety monitoring without adding confusion or weakening transparency.
-
Embracing Gentle Innovation: My Personal Journey in Treating Periodontitis
Hello to all my valued local patients and those who have traveled from afar. I’m Dr. Susan Pan, and I want to share my personal journey in transforming the way we treat periodontitis. Embracing gentle innovation has been at the heart of my practice, and it has reshaped how we approach this common yet serious condition. In my early years as a periodontist, I realized that traditional methods often left patients feeling anxious and overwhelmed. Driven by a desire to change this, I embarked on a path to discover more patient-friendly techniques. Through continuous learning and collaboration with forward-thinking professionals, I integrated minimally invasive procedures that prioritize comfort and effectiveness. One of the most significant breakthroughs in my practice has been the incorporation of laser therapy. This technology not only reduces discomfort and healing time but also enhances precision in targeting affected areas. Patients have responded positively, noting the ease and efficiency of their treatment experiences. Moreover, I have embraced a holistic approach, understanding that oral health is deeply connected to overall well-being. By educating my patients about the links between periodontal health and systemic conditions, we empower them to take proactive steps in their care. For those who are ready to explore these innovative treatments, I invite you to learn more about my practice by visiting [Excel Dental](https://
-
Why Some People Never Feel Pain: What Congenital Insensitivity to Pain Teaches Us About the Human Body
A rare condition called congenital insensitivity to pain may sound like a superpower. In reality, it can be life-threatening. Here’s what researchers know, what remains a mystery, and what it means for everyday health.
-
Aurora Sheboygan Prices – ELOTUZUMAB 300 MG IV SOLR is $156.36
At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding ELOTUZUMAB 300 MG IV SOLR, which is classified under revenue code 250 and associated with CPT code J9176, the designated fee stands at $156.36. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.